Jeffrey Fraser, DO
Family Medicine · Venice, FLNPI 1740292762
Payments from drug & device makers
Across 158 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$363
- GSK$267
- Pfizer$240
- Boehringer Ingelheim$211
- Amgen$188
- Merck$174
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,543100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $363 |
| GSK | 19 | $267 |
| Pfizer | 16 | $240 |
| Boehringer Ingelheim | 17 | $211 |
| Amgen | 12 | $188 |
| Merck | 15 | $174 |
| AstraZeneca | 9 | $173 |
| Bayer | 6 | $148 |
| Lilly USA, LLC | 9 | $145 |
| Astellas Pharma US Inc | 6 | $107 |
| Kowa Pharmaceuticals America, Inc. | 4 | $68 |
| AbbVie(2 entities) | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Abbott | 2 | $41 |
| Dexcom, Inc. | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Exact Sciences | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
How this compares
$2,543 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $254,108 |
| XareltoRivaroxaban | 48 | $62,139 |
| OzempicSemaglutide | 25 | $59,357 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $56,382 |
| JanuviaSitagliptin Phosphate | 27 | $46,294 |
| JardianceEmpagliflozin | 30 | $41,943 |
| ProliaDenosumab | 22 | $37,874 |
| MyrbetriqMirabegron | 39 | $28,786 |
| TrulicityDulaglutide | 16 | $23,510 |
| LinzessLinaclotide | 14 | $18,695 |
| FarxigaDapagliflozin Propanediol | 20 | $16,253 |
| Atorvastatin Calcium | 956 | $9,279 |
| TradjentaLinagliptin | 14 | $6,824 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,436 |
| Levothyroxine Sodium | 521 | $5,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $240 | $254,108204 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $267 | $62,81846 claims |
| Johnson & JohnsonXarelto | $22 | $62,13948 claims |
| Novo NordiskOzempic | $363 | $59,35725 claims |
| Boehringer IngelheimJardiance, Tradjenta | $211 | $48,76744 claims |
| MerckJanuvia | $174 | $46,29427 claims |
| AmgenProlia | $188 | $37,87422 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $28,78639 claims |
| Lilly USA, LLCTrulicity | $145 | $23,51016 claims |
| AbbVieLinzess, Synthroid | $58 | $21,36559 claims |
| AstraZenecaFarxiga | $173 | $16,25320 claims |
| Sanofi-aventis U.S. LLCLantus | $52 | $2,27421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Venice
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.